Eso Yuji, Nakano Shigeharu, Mishima Masako, Arasawa Soichi, Iguchi Eriko, Takeda Haruhiko, Takai Atsushi, Takahashi Ken, Seno Hiroshi
Department of Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Quant Imaging Med Surg. 2021 Jun;11(6):2766-2774. doi: 10.21037/qims-20-965.
Contrast-enhanced computed tomography (CECT) is generally used to evaluate the response to treatment of hepatocellular carcinoma (HCC); however, CECT is unsuitable for the early prediction of therapeutic effects and frequent monitoring. We aimed to investigate the usefulness of our simplified method for the quantification of tumor vascularity using contrast-enhanced ultrasound (CEUS) with perfluorobutane microbubbles [Sonazoid (GE Healthcare, Oslo, Norway)] to predict the therapeutic effect of lenvatinib. Among the 13 patients studied, nine who had more than a 20% reduction in tumor vascularity within 2 weeks of starting treatment experienced complete response or partial response at 8-12 weeks as assessed by CECT. In contrast, three patients without reductions and one patient with only a slight decrease in tumor vascularity had a poor response to lenvatinib. Quantitative assessment of tumor vascularity by our simplified CEUS-based method could be a useful predictor of therapeutic responses to lenvatinib in patients with HCC.
对比增强计算机断层扫描（CECT）通常用于评估肝细胞癌（HCC）的治疗反应；然而，CECT不适用于治疗效果的早期预测和频繁监测。我们旨在研究使用全氟丁烷微泡[声诺维（通用电气医疗集团，挪威奥斯陆）]的对比增强超声（CEUS）对肿瘤血管进行量化的简化方法预测乐伐替尼治疗效果的有效性。在研究的13例患者中，9例在开始治疗后2周内肿瘤血管减少超过20%，经CECT评估，在8-12周时出现完全缓解或部分缓解。相比之下，3例肿瘤血管未减少的患者和1例肿瘤血管仅略有减少的患者对乐伐替尼反应不佳。通过我们基于CEUS的简化方法对肿瘤血管进行定量评估可能是HCC患者对乐伐替尼治疗反应的有用预测指标。
